Repligen (RGEN)
(Delayed Data from NSDQ)
$161.67 USD
-4.00 (-2.41%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $161.66 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Price, Consensus and EPS Surprise
RGEN 161.67 -4.00(-2.41%)
Will RGEN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RGEN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RGEN
Repligen's (RGEN) Q2 Earnings & Revenues Meet Estimates
Repligen (RGEN) Q2 Earnings Meet Estimates
RGEN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Exact Sciences (EXAS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Analysts Estimate Repligen (RGEN) to Report a Decline in Earnings: What to Look Out for
Repligen (RGEN) Soars 4.4%: Is Further Upside Left in the Stock?
Other News for RGEN
Biotech Alert: Searches spiking for these stocks today
Biotech Alert: Searches spiking for these stocks today
Repligen’s Buy Rating Affirmed Amid Strong Growth and Strategic Initiatives
Buy Rating Reaffirmed for Repligen Amid Strong Growth Prospects and Market Resilience
Repligen (RGEN) Shares Cross Above 200 DMA